Strategies to mitigate this risk may include selecting tumour types with low angiogenic dependency, monitoring tumour vascular markers before and during treatment, and combining GLP-1 RAs with anti-angiogenic therapies to offset potential pro-vascularisation. Here, GCG is linked to neoplasm.